Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced on August 5, 2015, a significant amendment to its warrant agreement with Morgan Stanley. This Second Amendment allows Regeneron to reduce the number of outstanding warrants held by Morgan Stanley by up to 90%, which could result in a payment of up to $399.0 million. This move is designed to manage potential dilution and financial obligations associated with warrants issued in 2011 related to convertible senior notes and hedging transactions. The amendment provides flexibility for Regeneron to settle these obligations. Payments can be made in cash or in shares of Regeneron's common stock, subject to a cap on the total number of shares that can be delivered. This provides Regeneron with strategic options for managing its capital structure and potential shareholder dilution over the defined transaction period.
Key Highlights
- 1Regeneron entered into a Second Amendment to its Warrant Agreement with Morgan Stanley on August 5, 2015.
- 2The amendment allows for the reduction of up to 909,112 outstanding warrants held by Morgan Stanley, representing up to 90% of the remaining warrants.
- 3Regeneron may pay up to $399.0 million to Morgan Stanley for the reduction of these warrants.
- 4The reduction and payment will occur over a transaction period from August 6, 2015, to November 3, 2015.
- 5Regeneron has the option to satisfy its payment obligations either in cash or by delivering shares of its common stock.
- 6A cap of 250,000 shares is in place for the total number of common shares Regeneron can deliver for settlement and to cover any shortfalls.
- 7This amendment aims to manage potential dilution and financial liabilities related to previously issued convertible notes and hedging activities.